Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Section Navigation
			
			CDC Home








ACIP Recommendations						Print
																Related Pages
										The ACIP develops recommendations on how to use vaccines to control disease in the United States.
The Committee’s recommendations are forwarded to CDC’s Director and once adopted become official CDC policy. These recommendations are then published in CDC’s Morbidity and Mortality Weekly Report (MMWR).
ACIP RecommendationsComplete list of ACIP recommendations published in the MMWR.
Immunization SchedulesLinks to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
ACIP Shared Clinical Decision-Making FAQsFrequently asked questions about ACIP’s recommendations based on shared clinical decision-makingRecent Meeting RecommendationsACIP approved the following recommendations by majority vote and they have been adopted by the CDC Director. They will be published in MMWR and reflected in CDC’s print and digital resources in the coming months.
**October 25-26, 2023**
**Meningococcal Vaccines**
Pfizer’s MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit.*
*1) Healthy individuals aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccination, 2) individuals aged 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines.
**Mpox Vaccines**
ACIP recommends vaccination*with the 2-dose§ JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox¶
*This is an interim recommendation that ACIP will revisit in 2-3 years
§Dose 2 administered 28 days after dose 1
¶Persons at risk:
Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
A new diagnosis of ≥1 sexually transmitted disease
More than one sex partner
Sex at a commercial sex venue
Sex in association with a large public event in a geographic area where mpox transmission is occurring
Sexual partners of persons with the risks described in above
Persons who anticipate experiencing any of the above
**Combined Immunization Schedules**
Approve the *Recommended Child and Adolescent Immunization Schedule, United States, 2024* and the *Recommended Adult Immunization Schedule, United States, 2024*.
These recommendations have been adopted by the CDC Director on October 26, 2023 and are now official.
**February 22-24, 2023**
ACIP approved the following recommendation by majority vote at its February 22-24, 2023 meeting:
ACIP recommends the 2-dose* JYNNEOS vaccine series for persons aged 18 years and older at risk of mpox during an mpox outbreak§.
*Dose 2 administered one month after dose 1§Public health authorities determine whether there is an mpox outbreak; a single case may be considered an mpox outbreak at the discretion of public health authorities. Other circumstances in which a public health response may be indicated include ongoing risk of introduction of mpox into a community due to disease activity in another geographic area.This recommendation has been adopted by the CDC Director and is now official.
							
					
							Last Reviewed:  January 5, 2024						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue